GeoVax Corporate Overview

NASDAQ: GOVX
Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
GeoVax

A Compelling Opportunity

• Unmet Medical Needs
• Differentiated products
• Near-term stock catalysts
• Proven Leadership

Phase 2 clinical-stage biotechnology company advancing novel immunotherapies and vaccines against a wide range of cancers and infectious diseases

• Two products in multi-site Phase 2 clinical programs addressing unmet medical needs
  • Gedepitin®, targeting advanced head & neck cancers
    • Orphan Drug Status granted
  • GEO-CM04S1, next-generation COVID-19 vaccine
    • Targeting patients with unmet immune protection from existing COVID-19 vaccines

• Near-term milestones (< 12 months)

• Experienced, recognized leadership in transformative value development

• Ideal candidate for acquisition/partnering

• Well capitalized, no debt
NextGen COVID Vaccine
- Targeting high-risk groups: elderly & immune compromised
- Focused on more robust immune protection and improved durability

Advanced Head & Neck Cancer Therapy
- Improved quality of life via tumor shrinkage

Mpox & Spox Vaccine
- Fulfilling current supply gaps in meeting worldwide demand

GeoVax
Addressing Unmet Medical Needs
2023 Milestones – Key Value Catalysts

**Gedeptin® (Advanced Head and Neck Cancers)**
- Completion of FDA-funded portion (10-patients) of Ph 2 trial
- Regulatory discussions re expanded Ph 2 trial & expedited registration pathway

**GEO-CM04S1 (Next-Generation COVID-19 Vaccine)**
- Multi-site expansion of Ph 2 booster trial & completion of enrollment
- Multi-site expansion of Ph 2 Immunocompromised trial
- Initiation of 3rd Ph 2 trial among patients with Chronic Lymphocytic Leukemia (CLL)
- Regulatory discussion re expedited registration pathway (immunocompromised patients)

**GEO-MVA (Mpox; Spox)**
- Clarify expedited regulatory registration pathway

**GEO Continuous Cell-line MVA Manufacturing (transformative)**
Initial Indication: Advanced Head and Neck Cancers

~ 67K H&N Cancer new cases annually in US¹
~ 15K H&N Cancer deaths annually in US¹

~ 900K H&N Cancer new cases annually Worldwide²
~ 400K H&N Cancer deaths annually Worldwide²

Source: NIH: National Cancer Institute

(1) American Cancer Society Cancer Facts & Figures, 2023
(2) International Agency for Research on Cancer; World Health Organization, 2023
Mechanism of Action - Gedeptin®

(GDEPT: Gene-Directed Enzyme Prodrug Therapy)

- Unprecedented level of cell killing activity
- Novel tumor killing mechanism
- Destroys refractory solid tumors

Gedeptin® (Ad/PNP)

<table>
<thead>
<tr>
<th>Plasma enzymes</th>
</tr>
</thead>
<tbody>
<tr>
<td>F-araAMP (Fludara, Fludarabine phosphate)</td>
</tr>
<tr>
<td>F-araA (Fludarabine)</td>
</tr>
<tr>
<td>E. coli PNP in tumor cells</td>
</tr>
<tr>
<td>Fluoroadenine</td>
</tr>
</tbody>
</table>

Fludarabine
COVID Vaccine

GEO-CM04S1

Product Profile

• Broader, more durable protection than existing authorized vaccines
• Uniquely inducing both antibody and cellular immune responses

GeoVax platform (MVA): recognized safety, potent, durable, minimal refrigeration
Humoral and cellular immune responses contribute to protection against SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19). Plus signs denote the relative importance of antibodies and T cells for protection in each category of disease severity, with more plus signs indicating greater importance.

Barouch DH, N Engl J Med 2022; 387:1011-1020
Targeting Immunocompromised Patients

Individuals unable to mount a robust, durable antibody response to the existing COVID-19 vaccines and monoclonal antibody therapies as a result of their medical conditions:

- Cancers
- Renal disease
- HIV
- Sickle cell anemia
- Autoimmune disease (e.g., Lupus)
- Multiple sclerosis
- Transplantation (e.g., immune suppressive therapy)
- Diabetes
- Etc.

15 million estimated in the U.S.
240+ million estimated Worldwide

Source: Airfinity Limited
GEO-CM04S1 – Phase 2 Clinical Trials

Phase 2: Immunocompromised
• Patients with hematologic malignancies receiving stem-cell transplantation or CAR-T therapy
  • Highest at-risk groups for severe infection, hospitalization and death
  • Primary vaccine in direct comparison to mRNA vaccines

Phase 2: Booster
• Healthy population following vaccination with an mRNA vaccine
  • Potential for broader and more durable protection versus multiple, continuous mRNA doses

Phase 2: Booster among Chronic Lymphocytic Leukemia (CLL) Patients
• High at-risk population with abated antibody response
  • Major, currently unmet, medical need for alternative immune enhancement response (e.g., T-cells)
White House launching $5 billion program to speed coronavirus vaccines

‘Project Next Gen’ would succeed ‘Operation Warp Speed’ with a mission to develop next-generation vaccines and therapies

By Dan Diamond

Updated April 10, 2023 at 5:57 a.m. EDT | Published April 10, 2023 at 4:10 p.m. EDT

Morning Briefing

Summaries of health policy coverage from major news organizations

TUESDAY, APR 11, 2023

‘Project Next Gen’ Aims To Expedite Vaccines To Combat Future Coronaviruses

White House to invest $5 billion in next-generation COVID vaccines. Here’s why we need new ones.

Project NextGen seeks to develop longer-lasting vaccines that protect against all COVID variants and future coronaviruses. But doing this will likely be more difficult than it sounds, experts say.

By Karen Weintraub

USA TODAY

Published 8:36 a.m. ET April 10, 2023 | Updated 11:37 a.m. ET April 11, 2023
GEO-MVA

Focused on expedited registration for 1st U.S. vaccine against Mpox & Spox

Nov 9, 2022

GeoVax Secures Rights from NIH for MVA Use Against Mpox & Spox
MVA vaccines are currently manufactured via a sub-optimal, antiquated process (using Chicken Embryonic Fibroblasts)

- Time consuming
- Low capacity, low yield

GeoVax is focused on transforming MVA production to high-yield, high-capacity continuous cell line manufacturing system

- Providing ability to address epidemics and pandemics
- Providing additional/alternative for products stockpiled
- Low-cost, scalable versatility for broad MVA-vaccine and immunotherapy applications
# Leadership Team

**David A. Dodd**  
CEO, President & Chairman  
- Has led the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5B in financial transactions, and over $5B in incremental enterprise growth  
- Successful IPO listings, re-capitalizations, and corporate developments in multiple international jurisdictions  
  - As President, CEO at Serologicals Corporation (Nasdaq: SERO), market value increased from $85M to $1.5B, concluding in an all-cash sale to Millipore Corporation  
  - As President, CEO Solvay Pharmaceuticals, Inc., value increased (5 yrs) from $100M to $2.5B  
- Executive roles with Wyeth-Ayerst Laboratories (now Pfizer), Bristol-Myers Squibb, and Abbott Laboratories

**Kelly McKee, MD**  
Chief Medical Officer  
Colonel US Army (retired)  
- Extensive experience in clinical development in infectious diseases including antiviral drugs/biologics, emerging infectious diseases, COVID-19 vaccines & therapeutics, biothreat countermeasures, sexually transmitted infections  
- Former Director of Medical programs at U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)  
- Former VP, Vaccines and Public Health, Infectious Diseases and Vaccines Center of Excellence at Quintiles

**Mark Newman, PhD**  
Chief Scientific Officer  
- Participated/directed teams responsible for the transition of 10 vaccine or vaccine-related products (protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants) from the research stage to Phase 1 & 2 clinical testing  
- Principal Investigator on multiple USA government and foundation grants and contracts  
- Co-authored more than 100 scientific papers, reviews and book chapters

**John Sharkey, PhD**  
VP Business Development  
- Executive management, technical development, regulatory and business development services to small and mid-size pharma and medical device companies  
- Key contributor to the development, acquisition, or divestment of multiple products with annual revenues ranging from $5M to more than $2B dollars  
- Has led completion of GeoVax’s two transactions in the areas of COVID-19 (Phase 2) and Oncology (Phase 2)

**Mark Reynolds, CPA**  
Chief Financial Officer  
- Held CFO positions in multiple private and public healthcare companies  
- Directed GeoVax’s capital development activities raising $37M in 2022
Board of Directors & Advisors

David A. Dodd
CEO, President & Chairman

- Has led the approval of 10+ NDAs, 15+ acquisitions & divestitures, in excess of $2.5B in financial transactions, and over $5B in incremental enterprise growth

Randall D. Chase, PhD
Board of Directors

- Former President and CEO of Immunovaccine, Inc.
- Former president of Shire Biologics, North American Vaccine, Pasteur Merieux Connaught, and Quadra Logic Technologies, Inc.

Dean G. Kollintzas
Board of Directors

- Intellectual property attorney specializing in biotechnology and pharmaceutical licensing, FDA regulation, and corporate/international transactions.

Nicole Lemerond, CFA
Board of Directors

- Financial executive experienced in investment management, private equity, investment banking, mergers/acquisitions, and leveraged finance

Robert T. McNally, PhD
Board of Directors

- Former CEO of Cell Dynamics LLC
- Co-founder and Senior Vice President of Clinical Research for CryoLife, Inc

Jayne Morgan, MD
Board of Directors

- Cardiologist and Executive Director of Health & Community Education at the Piedmont Healthcare Corporation in Atlanta, GA
- Adjunct Assistant Professor of Medicine at The Morehouse School of Medicine

John (Jack) N. Spencer, Jr., CPA
Board of Directors

- Former Partner at Ernst & Young LLP
- Extensive experience as Audit Committee Chair on the Boards of life sciences companies.

Valerie Montgomery Rice, MD, FACOG
Special Advisor to the Chairman, CEO and Board of Directors

- President and CEO, Morehouse School of Medicine
- President Joe Biden appointment to The President’s Committee on the National Medal of Science
GeoVax
A Compelling Investment & Collaboration Opportunity

Phase 2 clinical-stage biotechnology company advancing novel immunotherapies and vaccines against a wide range of cancers and infectious diseases

• Two products in multi-site Phase 2 clinical programs addressing unmet medical needs
  • Gedeptin®, targeting advanced head & neck cancers
    • Orphan Drug Status granted
  • GEO-CM04S1, next-generation COVID-19 vaccine
    • Targeting patients with unmet immune protection from existing COVID-19 vaccines

• Near-term milestones (< 12 months)

• Experienced, recognized leadership in transformative value development
  • Ideal candidate for acquisition/partnering
  • Five analysts recommending BUY with 12-month target price average of $6/share

• Well capitalized, no debt
## Capitalization Highlights

*(as of 3/31/2023)*

### Fully Diluted Shares

<table>
<thead>
<tr>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Shares Outstanding</td>
<td>26.4 M</td>
</tr>
<tr>
<td>GOVXW Warrants ($5.00; 9/29/25)</td>
<td>1.8 M</td>
</tr>
<tr>
<td>Other Options/Warrants ($2.48 Avg)</td>
<td>12.5 M</td>
</tr>
</tbody>
</table>

### Balance Sheet

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash Balances</td>
<td>23.9 M</td>
</tr>
<tr>
<td>Debt</td>
<td>0 M</td>
</tr>
</tbody>
</table>
Successful Capital Development 2022
Strong IP for GeoVax Technology and Applications

Core Technology Platforms
• Modified Vaccinia Ankara (MVA)
  • MVA
  • MVA-VLP
  • Synthetic Modified Vaccinia Ankara (s-MVA)
• Gene-Directed Enzyme Prodrug Therapy (GDEPT)

Broad Product IP Applications
• Oncology
  • Solid tumors
  • HPV-associated cancer
• Infectious Diseases
  • COVID-19/SARS-CoV-2 & variants
  • Hemorrhagic fever (Ebola, Marburg, Sudan, Lassa)
  • Zika
  • Malaria
  • HIV

115 granted or pending patent applications spread over 24 patent families
MVA as a Vector Supports Development of “Next-generation” Vaccines

- Spike (S) protein as both the antibody and T cell immunogen
  - Neutralizing antibodies induced after two doses

- Nucleocapsid (N) as an additional T cell immunogen
  - Responses induced with a single dose
  - Epitopes are conserved Wuhan to Omicron
  - Antibodies specific for N also induced

Combination of Spike + Nucleocapsid provides coverage for Variants of Concern (VoCs) – Omicron, Delta, etc.

Other vaccine platforms (e.g., mRNA, etc.) are unable to encode multi-antigens into a single vaccine
GEO-CM04S1 Immunogenicity

Phase 1 Clinical Trial Data

Neutralizing Antibody

IFN Gamma Producing T cells

Spike

Nucleocapsid

COVID Vaccine

Phase 1 Clinical Trial Data

Neutralizing Antibody

IFN Gamma Producing T cells

Spike

Nucleocapsid

COVID Vaccine
The FDA Priority Review Voucher (PRV) Program established to incent the development of specific rare and neglected diseases (rare tropical diseases; rare pediatric diseases and priority medical countermeasures).

The PRV provides the owner an FDA review period of 6-months versus the standard 10-12-month review period.

A PRV can be sold to other companies that may wish to have such an accelerated FDA review related to a potential “block-buster” drug or vaccine.

Since the first PRV was granted in 2009, there have been approximately 57 PRVs granted. Beginning in 2014, the first PRV was sold; in total 30 PRVs have been sold since 2014, for an average value of approximately $124 million.

GeoVax candidates for Priority Review Vouchers include:
- Ebola, Lassa, Marburg,
- Sudan, Malaria and Zika

(1) GeoVax does not have a PRV, and must receive a drug approval to be eligible to receive one.